Mocetinostat (MGCD0103)

Catalog No.S1122 Synonyms: MG0103

Mocetinostat (MGCD0103) Chemical Structure

Molecular Weight(MW): 396.44

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 470 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  •  

    Comparison of MCAS ovarian cancer cells harboring control and CtBP2 knockdown shRNAs for sensitivity to chemotherapeutic agents. For each cell line, the MTT reading of the untreated cells was assigned as 100%. HDAC inhibitors: (a) Trichostatin A; (b) Vorinostat; (c) Belinostat; (d) MGCD0103; (e) valproic acid; and (f ) carboplatin, a non-HDAC inhibitor.

    Oncogene 2012 32, 3896-903. Mocetinostat (MGCD0103) purchased from Selleck.

    Class-specific histone deacetylase inhibition ameliorates cholesterol accumulation. Mutant fibroblasts (NPC-26) were incubated for 18 h in the presence of the HDAC class-specific inhibitors MC1568 and MGCD0103 (5 μM) and assessed for cholesterol accumulation by filipin fluorescence. Quantification of filipin fluorescence is expressed as arbitrary units. *, p<0.05, treated versus untreated cells by two-tailed Student,s t test.

    J Biol Chem 2011 286, 23842–23851. Mocetinostat (MGCD0103) purchased from Selleck.

  •  

    HDACI sensitivities in pancreatic cancer cell lines and the HPDE cells. Panels A–C: PANC-1 cells were harvested and lysed after incubation with a range of concentrations of MGCD0103 (0–1.0 uM), MC1568 (0–10 uM), or Tubastatin A (0–4 uM) for 96 h. Soluble proteins were analyzed on Western blots probed by anti-acetylated (ac)-H4, -H4, -ac-tubulin, or –b-actin antibody. Panel D: AsPC-1, BxPC-3, PANC-1, or the HPDE cells were cultured at 37’C for 96 h in complete medium in 96-well plates, with a range of concentrations of MGCD0103, MC1568, or Tubastatin A, and cell viabilities were determined using the MTT reagent.

    PLoS One 2012 7, e52095. Mocetinostat (MGCD0103) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don,t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or-β-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Mocetinostat (MGCD0103) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Mocetinostat (MGCD0103) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MGCD0103 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Mocetinostat (MGCD0103) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
0.15 μM 0.29 μM 0.59 μM 1.66 μM
In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z5VVQ5KGh? MmXaTWM2OD1|LkC0JO69VQ>? MVuyOlM4QDB|OB?=
BT549 NX7xVo9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHPfWo1QCCq MX7JR|UxRTRwM{ig{txO M2\vT|I3Ozd6MEO4
MCF7 NXHSUJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrDOFghcA>? MmTJTWM2OD1yLk[3JO69VQ>? M{S0SFI3Ozd6MEO4
T47D NFLneppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG0PEBp NEixUW9KSzVyPUGuNVch|ryP MkDoNlY{PzhyM{i=
MOLP8 M3rITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvidFZFPDhiaB?= MlvYTWM2OD1yLkdCtUAxNjB2zszN NFz1[ZAzPjB7MUWxPC=>
Panc1 NFfJR|VHfW6ldHnvckBCe3OjeR?= MXOwMlUwOS9{LkWg{txO MlexOFghcA>? MoDHSG1UVw>? MmjQeZBz\We3bHH0[ZMhdWmULUKwNy=> M4H0XVI2QDd{OUSx
Panc1 MYLGeY5kfGmxbjDBd5NigQ>? MkSxNE42NzFxMj61JO69VQ>? NHz2RYM1QCCq NHLHcW1FVVOR NYPISJpvemWmdXPld{BmgHC{ZYPzbY9vKG:oIGrFRlEhd25iYn;0bEBuWk6DIHHu[EBxem:2ZXnuJIxmfmWuwrC= NYfsPXBJOjV6N{K5OFE>
Panc1 NYnFWJZQSXCxcITvd4l{KEG|c3H5 MWSxxsDPxE1? NF\6TYs4OsLiaB?= NY[0Xo5{TE2VTx?= NHfmOXl{\W6|aYTpfoV{KFCjbnOxJINmdGy|IH\vdkBo\W2laYThZolv\S2rbnT1Z4VlKGGyb4D0c5Nqew>? MoP1NlU5PzJ7NEG=
Panc1 MnnPR4VtdCCYaXHibYxqfHliQYPzZZk> NHnGW5EyyqEQvF2= MXG3NuKhcA>? MVHEUXNQ MVrlcohidmOnczDn[Y1kcXSjYnnu[U1qdmS3Y3XzJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn MojZNlU5PzJ7NEG=
MMCs Mn7ZSpVv[3Srb36gRZN{[Xl? MWexJO69dQ>? M3nYU|AuPDhiaB?= MYTpcoNz\WG|ZYOgUnBTSSCycn;0[YlvKGW6cILld5Nqd28EoEKuO-KBmzNwNTDmc4xl MVSyOFQ2OTN5OB?=
MMCs MWLGeY5kfGmxbjDBd5NigQ>? M2rZV|AvPS9zIN88US=> M374eFI1KGh? M2\xOZNpd3e|IES1MYZwdGRic4TpcZVt[XSrb36gbY4h[0ePUDDs[ZZmdHN? MXeyOFQ2OTN5OB?=
MMCs M{P3VmZ2dmO2aX;uJGF{e2G7 NHXqbXAyyqEQvF2= MYmyOEBp NFj1[WdqdmO{ZXHz[ZMhUEGWIHHjeIl3cXS7 MYSyOFQ2OTN5OB?=
MMCs NYX0bWF5TnWwY4Tpc44hSXO|YYm= MWGxxsDPxE1? MnT2NlQhcA>? MVzheYdu\W62czDncI9j[WxiYXPleJlt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFMuUzlxMUSgLGg{NUt7L{G0ZYMqKGGwZDDIOE1MOTJiKFi0MWsyOmGlKR?= Ml;zNlQ1PTF|N{i=
MMCs M1rJb2Z2dmO2aX;uJGF{e2G7 MV:xxsDPxE1? MmTWOk0zPCCq M4\tWoRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdIOgeIhmKHS{aX3leIh6dGG2aX;uJIxmfmWuIH;mJGg{NUt7IDjIN{1MQW2nMzm= NILJeJgzPDR3MUO3PC=>
BxPC-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPtSWM2OD1zLkGg{txO MVmyNVM4PTZ5OR?=
AsPC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HIWmVEPTB;Mz65JO69VQ>? MVWyNVM4PTZ5OR?=
MiaPaca-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLBSWM2OD1yLk[g{txO MV[yNVM4PTZ5OR?=
Panc-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK4T4NUTUN3ME2xMlgh|ryP MlfGNlE{PzV4N{m=
PAXF 546L† MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTCcGlKTUN3ME2xMlUh|ryP M1HmT|IyOzd3Nke5
PAXF 1657L† MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXxSWM2OD1yLkOg{txO MkeyNlE{PzV4N{m=
HCT15 NV24W2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnTTIVKSzVyPUCuO{DPxE1? NVj6SHVlOjF|MUe0OVU>
HT-29 M3n6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvVTWM2OD1yLkeg{txO MWiyNVMyPzR3NR?=
SW48 NVPEeIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ERmlEPTB;MD64JO69VQ>? NUTxcoNHOjF|MUe0OVU>
SW620 NGq2R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HHNWlEPTB;MTFOwG0> NVrTR5Y5OjF|MUe0OVU>
HMEC MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF7IN88US=> M2TCUlIyOzF5NEW1
ANBL6  MULGeY5kfGmxbjDBd5NigQ>? NFvsbm8yyqEQvF2= NIn3SXQzPCCq NITVZlZmdmijbnPld{A2NUGFLXnu[JVk\WRiTVHHSU1COyCpZX7lJIV5eHKnc4Ppc44> MnjMNlEyPzF6MkG=
LP1 NFTNRnVHfW6ldHnvckBCe3OjeR?= NWPNbW06OcLizszN NWXafppwOjRiaB?= M2LreYVvcGGwY3XzJFUuSUNvaX7keYNm\CCPQVfFMWE{KGenbnWg[ZhxemW|c3nvci=> M4fqWlIyOTdzOEKx
HD-LM2 NYnacVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqzUI4zPzMEoHi= MXzEUXNQ M33oN2lEPTB;MT64PEDPxE1? MWOyNFg5ODFyNx?=
L428 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf1O|LDqGh? NXTnVIJlTE2VTx?= M2LFbWlEPTB;MT65OkDPxE1? M1fXbFIxQDhyMUC3
KM-H2 NHXMW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC3NuKhcA>? MWrEUXNQ NI[5TXlKSzVyPUKuPFYh|ryP M{G5cVIxQDhyMUC3
HD-LM2 NY\mbZRpTnWwY4Tpc44hSXO|YYm= NXr4O2RJOC5zLUKg{txO MUKyOEBpyqB? MmDYSG1UVw>? MULzbI94eyCjY3X0fYxifGmxbjDv[kBpcXO2b37lJFMh[W6mIIXwdoVofWyjdHnvckBw\iC2aHWgZ4VtdCCleXPs[UBz\We3bHH0c5J6KHC{b4TlbY4heDJz MoX4NlA5QDBzMEe=
L428 M4LDSGZ2dmO2aX;uJGF{e2G7 NFfB[|kxNjFvMjFOwG0> NF;jVWczPCCqwrC= Mm\1SG1UVw>? MoTPd4hwf3NiYXPleJlt[XSrb36gc4YhcGm|dH;u[UA{KGGwZDD1dJJm\3WuYYTpc44hd2ZidHjlJINmdGxiY4njcIUhemWpdXzheI9zgSCycn;0[YlvKHB{MR?= NU\Ndoc5OjB6OECxNFc>
KM-H2 M4DleWZ2dmO2aX;uJGF{e2G7 NF;wRXIxNjFvMjFOwG0> NXXjRlhNOjRiaNMg M2[0ZmROW09? MlLwd4hwf3NiYXPleJlt[XSrb36gc4YhcGm|dH;u[UA{KGGwZDD1dJJm\3WuYYTpc44hd2ZidHjlJINmdGxiY4njcIUhemWpdXzheI9zgSCycn;0[YlvKHB{MR?= M{\QOlIxQDhyMUC3
HD-LM2 MkHoRZBweHSxc3nzJGF{e2G7 M4rYcFAvOS9yLkWvNUDPxE1? M4ntXlQ5KGh? NFLZRZVFVVOR Mo\5bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MnL3NlA5QDBzMEe=
L428 M4PSU2Fxd3C2b4Ppd{BCe3OjeR?= NH;1W48xNjFxMD61M|Eh|ryP NIK2Tmo1QCCq M4TmdGROW09? NYHVU|ZLcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NUT5RZVGOjB6OECxNFc>
KM-H2 MULBdI9xfG:|aYOgRZN{[Xl? M2fz[lAvOS9yLkWvNUDPxE1? MX20PEBp NVrHNFBtTE2VTx?= MmfzbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NXzpc25iOjB6OECxNFc>
HD-LM2 M1XIe2Z2dmO2aX;uJGF{e2G7 NFG1O3oyyqEQvF2= MoKxNlQwPDhiaB?= NHm1cIRFVVOR NVvBeVFN\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>? MorJNlA5QDBzMEe=
L428 M1[zcmZ2dmO2aX;uJGF{e2G7 M3y3e|HDqM7:TR?= NEPtWpczPC92ODDo NGi0cJZFVVOR M2PFWIRwf26{ZXf1cIF1\XNiWFnBVEwh[WO2aY\heIVlKGOjc4Dhd4V{KDliYX7kJFM> MVGyNFg5ODFyNx?=
KM-H2 M4H6VWZ2dmO2aX;uJGF{e2G7 MlHxNeKh|ryP NYTUNHp7OjRxNEigbC=> M4G2dmROW09? NFftZYpld3ewcnXneYxifGW|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{ MVeyNFg5ODFyNx?=
HD-LM2 MXTGeY5kfGmxbjDBd5NigQ>? MX:wMlUwOSEQvF2= NHL0OoIzPC92ODDo MVfEUXNQ NIWzbJh2eHKnZ4XsZZRmeyCWTl[t{tEh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> Moq5NlA5QDBzMEe=
L428 NF7OdnVHfW6ldHnvckBCe3OjeR?= M4T6ZlAvPS9zIN88US=> MnPMNlQwPDhiaB?= Mlf2SG1UVw>? MofCeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NXvoSnZYOjB6OECxNFc>
KM-H2 MXvGeY5kfGmxbjDBd5NigQ>? NXLzNlVZOC53L{Gg{txO MoDoNlQwPDhiaB?= NEPMOpFFVVOR NEHKb5l2eHKnZ4XsZZRmeyCWTl[t{tEh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> M2nUcVIxQDhyMUC3
HD-LM2 M3LLemZ2dmO2aX;uJGF{e2G7 Ml7ENeKh|ryP MljpNE4zPS12ODDo NXjhSoVWTE2VTx?= MUXhZ5RqfmG2ZYOgUmYuc0J? MmTRNlA5QDBzMEe=
L428 NEeyWWVHfW6ldHnvckBCe3OjeR?= M17GdFHDqM7:TR?= NV7vWYF7OC5{NT20PEBp M3;xXWROW09? M1\0OoFkfGm4YYTld{BPTi2tQh?= M2m1ZlIxQDhyMUC3
KM-H2 NFS1c3dHfW6ldHnvckBCe3OjeR?= MlnoNeKh|ryP MYGwMlI2NTR6IHi= NGDRUmxFVVOR NX30WmFp[WO2aY\heIV{KE6ILXvC MlzYNlA5QDBzMEe=
H526 NYDaR4VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DVUGlEPTB;NEiwJI5O NXm2WppGOjB4OEK2OFM>
H146 NFHre2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN3IH7N M1TTXlIxPjh{NkSz
H82 M3rRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDwXW9zUUN3ME2yOVAhdk1? MUeyNFY5OjZ2Mx?=
DMS114 NGfFdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfkeZFKSzVyPU[0NEBvVQ>? NXzObFl1OjB4OEK2OFM>
HeLa NWjTUVBNTnWwY4Tpc44hSXO|YYm= NH7rWoMxNjNvMUCg{txO MkHZPEBp M2Xvd2ROW09? NETTZlhqdmO{ZXHz[ZMh[WOndInsZZRm\CCKMzDLPUApUDONOVHjLUBifCBzMDFOwG0> M1m3eFIxPTN6OESw
HeLa M3z0O2Z2dmO2aX;uJGF{e2G7 NWPCN5g3OC5|LUGwJO69VQ>? M4T6fFghcA>? NUn5eYRsTE2VTx?= NGPUdHpqdmO{ZXHz[ZMh[2G|cHHz[UA{KGGwZDC3JIFkfGm4YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> M2PWUFIxPTN6OESw
HeLa MojvSpVv[3Srb36gRZN{[Xl? NGXNNFEyOCEQvF5CpC=> NVviTW1DPi9zMj:yOEBp MVLEUXNQ MlHFbY5lfWOnczDtbZRwfGmlIHHjZ5VufWyjdHnvckBidmRiZHXsZZlm\CCyMkGg[ZhxemW|c3nvci=> M3jxSFIxPTN6OESw
HeLa  NHvoRpdHfW6ldHnvckBCe3OjeR?= M{XBe|ExKM7:TdMg NFnEeIU4KGh? M2\4fmROW09? Mm[3[Il{enWydIOgco9zdWGuIIPwbY5ldGViY3jlZ4txd2mwdDDmeY5kfGmxbh?= MX[yNFU{QDh2MB?=
PBMC  NF7PclJCeG:ydH;zbZMhSXO|YYm= NITOfFcxNjVxMj:zJO69VQ>? MUSyOE81QCCq MYPpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NIfZZ5gzODRyNkm0Oy=>

... Click to View More Cell Line Experimental Data

In vivo MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. [1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. [2]

Protocol

Kinase Assay:[1]
+ Expand

HDAC enzyme assay in vitro:

The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:[1]
+ Expand
  • Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells
  • Concentrations: 0-60 μM
  • Incubation Time: 72 hours
  • Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO2. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing H1437 tumors
  • Formulation: PBS acidified with 0.1 M HCl or PEG400/0.2 M HCl saline, 40:60
  • Dosages: 80 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL (32.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% Propylene glycol
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.44
Formula

C23H20N6O

CAS No. 726169-73-9
Storage powder
Synonyms MG0103

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02993991 Not yet recruiting Squamous Cell Carcinoma, Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral Cavity University Health Network, Toronto|Mirati Therapeutics Inc.|AstraZeneca January 2017 Phase 1
NCT02954991 Recruiting Carcinoma, Non-Small-Cell Lung Mirati Therapeutics Inc. November 2016 Phase 2
NCT02805660 Recruiting Advanced Cancer Mirati Therapeutics Inc. May 2016 Phase 1|Phase 2
NCT02303262 Active, not recruiting Metastatic Leiomyosarcoma Sarcoma Alliance for Research through Collaboration September 2015 Phase 2
NCT02429375 Recruiting Hodgkin Lymphoma Memorial Sloan Kettering Cancer Center|MethylGene Inc. April 2015 Phase 1|Phase 2
NCT02236195 Completed Urothelial Carcinoma Mirati Therapeutics Inc. October 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) supplier | purchase Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) cost | Mocetinostat (MGCD0103) manufacturer | order Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID